Definium says LSD-based DT120 reduces GAD symptoms in late-stage study
Definium Therapeutics (DFTX) said DT120, given as a single 100-microgram dose, reduced symptoms of generalized anxiety disorder and marked the company’s second successful late-stage study for the condition.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.